Achieve Life Sciences, Inc. (ACHV) Sets Yearly Low; Strong Momentum for Sellers

June 13, 2018 - By Clifton Ray

The stock of Achieve Life Sciences, Inc. (NASDAQ:ACHV) hit a new 52-week low and has $6.46 target or 7.00 % below today’s $6.95 share price. The 6 months bearish chart indicates high risk for the $8.97 million company. The 1-year low was reported on Jun, 13 by If the $6.46 price target is reached, the company will be worth $627,970 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 6.08% or $0.45 during the last trading session, reaching $6.95. About 67,813 shares traded or 35.43% up from the average. Achieve Life Sciences, Inc. (NASDAQ:ACHV) has declined 74.49% since June 13, 2017 and is downtrending. It has underperformed by 87.06% the S&P500.

More recent Achieve Life Sciences, Inc. (NASDAQ:ACHV) news were published by: which released: “42 Stocks Moving In Thursday’s Mid-Day Session” on May 24, 2018. Also published the news titled: “Achieve Life Sciences, Inc. Announces Reverse Stock Split” on May 23, 2018.‘s news article titled: “28 Stocks Moving In Wednesday’s Mid-Day Session” with publication date: June 06, 2018 was also an interesting one.

Achieve Life Sciences, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company has market cap of $8.97 million. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: